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IntroductIon
Mycophenolic acid (MPA) is the active metabolite of mycophenolate mofetil (MMF) that inhibits type II inosine monophosphate dehydrogenase, a rate-limiting enzyme during the de novo biosynthesis of guanosine nucleotide. [1] The inhibition in nucleotide synthesis eventually leads to the inhibition of T and B lymphocyte proliferation. MMF is an immunosuppressive agent that is widely used in the treatment of allogeneic transplantations and autoimmune diseases, especially in systemic lupus erythematosus (SLE) and lupus nephritis. [2] [3] [4] Intravenous cyclophosphamide (CYC) plus steroid has been recognized as the standard protocol for severe lupus nephritis. [5] Unfortunately, this strategy has been usually
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correlated with severe opportunistic infections. [6, 7] Recent studies suggested that patients treated with MMF plus glucocorticoid exhibited better clinical outcomes as well as lower infection incidences than patients with glucocorticoid in combination with CYC or azathioprine (AZA). [6] [7] [8] Previous results demonstrated that cytokine levels could be used to evaluate the immune status in patients with chronic heart failure or those exposed to immunosuppressants. [9] [10] [11] The previous study showed that dexamethasone (DEX) reduced the release of multiple cytokines, including interleukin (IL)-1β, IL-2, IL-5, IL-6, IL-8, IL-17, IL-10, IL-13 and interferon-γ, granulocyte-colony stimulating factor. Surprisingly, MPA in association with phytohemagglutinin (PHA) increased the secretion of IL-1β even though under the condition with DEX, [9] which contradicted the traditional conception that immunosuppressants inhibit the secretion of inflammatory factors.
IL-1β is the "master" cytokine mainly produced by monocytes and macrophages in response to inflammatory stimuli such as lipopolysaccharide (LPS) and plays an essential role in innate and adaptive immune responses. [12, 13] As IL-1β is required for the efficient clearance of infected bacteria, we believe that increased IL-1β may contribute to less infection in MMF-treated patients. However, it is unknown how MPA leads to the increased IL-1β release.
Different from most canonically released cytokines such as tumor necrosis factor (TNF)-α, IL-2, and IL-12 that are dependent on the endoplasmic reticulum and Golgi apparatus, IL-1β is more slowly released through a nonclassical secretory pathway. [13, 14] However, the production of IL-1β is tightly controlled by at least three distinct steps. The initial events involve the production of the NOD-like receptor pyrin domain containing-3 (NLRP3) and precursor interleukin-1β (pro-IL-1β) through the activation of Toll-like receptor 4. Second, the activation of inflammasome mediates the autoactivation of pro-caspase-1 (p45) to active caspase-1 (p20 and p10). Third, the cleavage of the 31,000 pro-IL-1β by caspase-1 (p20 or p10) results in the production and secretion of active form of 17,000 IL-1β. [15] In addition to IL-1β, IL-18 and IL-33 were also identified as the caspase-1 substrates. [15, 16] NLRP3 inflammasome is the most widely studied intracellular multiprotein complex that contains an NLRP3 sensor, an apoptosis-associated speck-like protein containing a caspase recruitment domain adaptor and a pro-caspase-1. The complex serves as a molecular platform for pro-caspase-1 autoactivation and regulates caspase-1 (p20)-mediated cleavage of pro-IL-1β. It has been known that NLRP3 inflammasome plays a crucial role in both immunity and inflammation. [17, 18] In this study, we first determined the effects of MPA in association with LPS on IL-1β production. Then, we explored whether the synergized effect on IL-1β production was mediated through the nuclear factor kappa B (NF-κB) pathway to produce more pro-IL-1β or through the triggering of NLRP3 inflammasome to enhance activation of caspase-1 that resulted in degradation of pro-IL-1β into mature IL-1β.
methods
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Materials
MPA, DEX, 6-mercaptopurine (6-MP, the active metabolite of AZA), CYC, LPS, adenosine triphosphate (ATP), and the specific inhibitor of caspase-1 ac-YVAD-cmk were all purchased from Sigma-Aldrich (St. Louis, MO, USA). Anti-human pro-IL-1β, phospho-NF-κB p65 (p-p65), total NF-κB p65, and β-actin antibodies were purchased from cell signaling technology (Danvers, USA). The antibodies against human caspase-1 and NLRP3 were purchased from Abcam (Cambridge, UK). The horseradish peroxidase (HRP)-conjugated secondary antibodies against mouse and rabbit were purchased from Cell Signaling Technology (Danvers, USA). Enzyme-linked immunosorbent assay (ELISA) kits for human cytokine detection were purchased from eBioscience (San Diego, USA). All cell culture reagents were from Gibco (Paisley, UK).
Isolation of human peripheral blood monocytes
Peripheral blood was obtained from healthy donors with informed consents. Peripheral blood mononuclear cells were isolated using Ficoll density gradient centrifugation and CD14+ monocytes separated with anti-CD14-conjugated microbeads (Miltenyi Biotec, Germany).
Cell culture
Monocytes and THP-1 cells (the human monocyte-like cells; 1 × 10 6 cells/ml) were cultured in Roswell Park Memorial Institute-1640 media containing 10% fetal bovine serum and 100 U/ml penicillin-streptomycin at 37°C in a humidified atmosphere containing 5% CO 2 . , and stimulated with LPS (1 µg/ml) for 12 h at 37°C in a humidified atmosphere containing 5% CO 2 . Then, the blood was centrifuged, and the supernatants collected and stored at −80°C until analysis.
Whole blood treatment
Cell treatment
Cells were treated with LPS (1 µg/ml) and/or MPA (5, 25, 75 µmol/L), ATP (5 mmol/L), and ac-YVAD-cmk (100 µmol/L). After 12 h, the supernatants were harvested and stored at −80°C for ELISA. One hour before LPS and MPA or ATP stimulation, ac-YVAD-cmk was added.
For Western blot analyses, the THP-1 cells were cultured in 6-well plates (4 × 10 6 cells/ml) in the absence or presence
, and ac-YVAD-cmk (100 µmol/L) as indicated.
Cytotoxicity assay
The cytotoxicity detection kit (Roche Diagnostics GmbH, Mannheim, Germany) was used for measuring the lactate dehydrogenase (LDH) activity. THP-1 cells were cultured for 12 h in the presence or absence of MPA (5, 25, and 75 µmol/L) and LPS (1 µg/ml). The assays were performed according to the manufacturer's instructions.
Cytokine measurements
Culture supernatants were collected after 3 and 12 h, and IL-1β was determined by ELISA according to the manufacturer's instructions.
Real-time quantitative polymerase chain reaction
The expression levels of IL-1β to β-actin RNA were measured with the LightCycler ® system (Roche, Mannheim, Germany). The total RNA was isolated from THP-1 cells with trizol extraction. The first strand cDNA synthesis kit for real-time polymerase chain reaction (RT-PCR) (TOYOBO, Japan) was used to prepare the first-strand cDNA according to the manufacturer 's instructions. The IL-1β fragment was amplified using primers: forward, 5'-AAACCCTCTGTCATTCGCTCCC-3'; reverse, 5'-ACACTGCTACTTCTTGCCCCCT-3'. The β-actin fragment was amplified using the following primer: forward, 5'-TGTTCCCCTTGGTATTTG-3'; reverse, 5'-CAAGACAAAACAACTGGT-3'. Data were analyzed using LightCycler Software, version 3.5 (Roche) and the program LinRegPCR, version 7.5 for analysis of RT-PCR data. To adjust for variations in the amount of input RNA, the IL-1β levels were normalized against the mRNA levels of the β-actin using the calculation 2 −ΔCt .
Western Blot analysis
Proteins were extracted from THP-1 cell lysates in radioimmunoprecipitation buffer (Sigma Aldrich) containing phosphatase and proteinase inhibitors for 30 min before centrifugation (13,200×g , 4°C, 10 min). Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The membranes were then blocked with 5% nonfat milk, washed with TBS plus Tween briefly, and incubated with primary antibodies (anti-pro-IL-1β, anti-p-p65, anti-p65, anti-caspase-1, and anti-NLRP3) at 4°C overnight. The anti-β-actin monoclonal antibody served as a loading control. Afterward, the membranes were incubated with secondary HRP-conjugated anti-rabbit/mouse IgG antibodies for 1 h at room temperature. Finally, an enhanced chemiluminescence plus chemiluminescent kit was used for the detection of the signal (Advansta, USA).
Statistical analysis
Data are presented as the mean ± standard error (SE). Significant differences between the mean values were evaluated using one-way analysis of variance followed by Student-Newman-Keuls multiple test or Dunnett's test for multigroups. All data were analyzed using SPSS software version 16.0 (SPSS Inc., Chicago, IL, USA). A P < 0.05 was considered as statistically significant.
results
Immunosuppressants distinctively influenced interleukin-1β secretion in undiluted whole blood, while only mycophenolic acid enhanced lipopolysaccharide-induced interleukin-1β release
The previous studies showed that MPA increased the secretion of IL-1β, while decreased the secretion of IL-2 and IL-13, in whole blood stimulated with PHA.
[9] Therefore, we determined whether MPA, DEX, CYC, and AZA, the immunosuppressants that are commonly used in the clinical treatment of SLE, have different effects on IL-1β secretion. We analyzed IL-1β secretion in human whole blood treated with LPS or the immunosuppressants or the combination of different doses of immunosuppressants with LPS for 12 h. The results showed that the level of IL-1β in control group was 10.78 ± 0.78 pg/ml, and incubation with immunosuppressants (DEX, MPA, 6MP, and CYC) alone did not induce detectable levels of IL-1β release (11.56 ± 1.61 pg/ml in DEX group, P = 1.000; 11.91 ± 0.95 pg/ml in MPA group, P = 0.980; 11.56 ± 2.79 pg/ml in 6MP group, P = 1.000; 11.56 ± 1.61 pg/ml in CYC group, P = 1.000). Compared to LPS stimulation alone (499.00 ± 67.11 pg/ml), DEX dose dependently inhibited the secretion of LPS-induced IL-1β (249.00 ± 28.91 pg/ml in LPS + 0.25 µmol/L DEX group, P = 0.024; 117.00 ± 10.35 pg/ml in LPS + 2.5 µmol/L DEX group, P = 0.010; 72.00 ± 3.61 pg/ml in LPS + 25.0 µmol/L DEX group, P = 0.010; Figure 1a) . In contrast to DEX, MPA significantly and dose dependently increased LPS-induced IL-1β release (686.00 ± 55.46 pg/ml in LPS + 5 µmol/L MPA group, P = 0.023; 1356.00 ± 70.65 pg/ml in LPS + 25 µmol/L MPA group, P < 0.001; 1938.00 ± 1.46 pg/ml in LPS + 75 µmol/L MPA group, P < 0.001; Figure 1b ), compared to LPS stimulation alone. However, 6-MP or CYC did not have any effects on the LPS-induced release of IL-1β (all P > 0.05; Figure 1c and 1d ). These data demonstrated that different immunosuppressants had distinctive effects on IL-1β secretion, while only MPA enhanced LPS-induced IL-1β release.
Mycophenolic acid enhanced lipopolysaccharide-induced interleukin-1β release in human monocytes and THP-1 cells
To further verify this phenomenon, monocytes and THP-1 cells were tested. Freshly isolated human monocytes and THP-1 cells were cultured for 12 h in the presence or absence of MPA or LPS and then the concentration of IL-1βin the supernatant detected by ELISA. Indeed, MPA synergistically enhanced LPS-stimulated IL-1β release in monocytes (669.00 ± 30.30 pg/ml in LPS + MPA group versus 284.00 ± 7.09 pg/ml in LPS group, F = 391.455, P = 0.014; Figure 2a) . Again, compared with LPS group (408.00 ± 35.50 pg/ml), the effects displayed an obviously dose-dependent pattern in THP-1 cells (685.00 ± 20.00 pg/ml in LPS + 5 µmol/L MPA group, P = 0.035; 742.00 ± 31.58 pg/ml in LPS + 25 µmol/L MPA group, P = 0.017; 1000.00 ± 65.59 pg/ml in LPS + 75 µmol/L MPA group, P = 0.024; Figure 2b ). MPA alone has no effect on the IL-1β mRNA expression (1.28 ± 0.20 fold, P > 0.05); LPS induced the expression of IL-1β mRNA 2761 fold after 3 h, compared with the control cells (F = 3.975, P = 0.048). However, the combination of LPS and MPA increased the IL-1β expression 3018 fold, which had the same effect with LPS group (F = 3.975, P = 0.834; Figure 2c ). In addition, the enhanced IL-1β release in the presence of MPA plus LPS was not due to passive "leakage" of IL-1β because there were no significant changes in LDH release (P > 0.05; Figure 2d) , indicating that the cell membrane was not impaired.
Mycophenolic acid did not affect the intracellular nuclear factor kappa B phospho-p65 and precursor interleukin-1β protein levels
To investigate the mechanisms by which MPA enhanced LPS-mediated IL-1β release, we next determined whether a combined treatment of MPA with LPS also increased the production of pro-IL-1β. The amount of phospho-p65 (p-p65) is commonly used as an indicator of NF-κB activation that is crucial for the production of pro-IL-1β. [19] Thus, we determined whether the treatment of MPA with LPS influenced the activation of p-p65. THP-1 cells were cultured as before in the presence or absence of LPS with or without MPA for 3 h. The cells were harvested, cell extracts prepared as previously described. The results showed that although LPS alone dramatically increased p-p65 and pro-IL-1β, MPA alone did not affect the expression of both molecules [ Figure 3a and 3b]. Nevertheless, MPA further dramatically increased the secretion of IL-1β as compared to LPS-treated cells (677.00 ± 13.98 pg/ml in LPS + MPA group vs. 378.00 ± 13.43 pg/ml in LPS group, F = 110.6, P = 0.001; Figure 3c ). These findings indicated that synergy of MPA with LPS to induce IL-1β release did not result from the enhancement of pro-IL-1β synthesis.
Mycophenolic acid augmented lipopolysaccharide -induced interleukin-1β secretion via activation of caspase-1
The experiments above prompted us to hypothesize that MPA induced IL-1β release through the activation of NLRP3 inflammasome. Hence, we investigated the effect of MPA on the NLRP3 inflammasome in THP-1 cells. Cells were cultured as before in the presence or absence of LPS with or without MPA for 3 h. LPS in association with ATP served as a positive control. [20] [21] [22] The results showed that both MPA and LPS increased the levels of NLRP3. Although LPS alone induced moderate amount expression of caspase-1 (p20), MPA dramatically increased its expression. Therefore, MPA in association with LPS constituted the strongest stimulation for caspase-1 (p20) [ Figure 4a ]. Accordingly, LPS alone induced a moderate release of IL-1β (329.00 ± 28.28 pg/ml), whereas coincubation of LPS with MPA constituted a very strong stimuli for IL-1β production (588.00 ± 41.99 pg/ml, F = 91.639, P = 0.035; Figure 4b ). Similar synergistic effects were also observed in the group treated with LPS and ATP (692.00 ± 3.91 pg/ml, F = 91.639, P = 0.024; Figure 4b ). Since caspase-1 (p20) has also been known to degrade pro-IL-18 into mature IL-18, we also tested IL-18 and found that MPA synergized with LPS to increase IL-18 release (1051.00 ± 44.79 pg/ml in LPS + MPA vs. 421.00 ± 28.74 pg/ml in LPS group, F = 263.46, P = 0.007; Figure 4c ). To further investigate whether MPA-activated caspase-1 was related to IL-1β and IL-18 secretion, THP-1 cells were preincubated with a specific caspase-1 inhibitor, ac-YVAD-cmk, for 1 h before stimulation with MPA and LPS. The results showed that ac-YVAD-cmk inhibited the activation of caspase-1 (p20) [ Figure 4d ] and significantly abrogated IL-1β (181.00 ± 45.24 pg/ml, F = 91.639, P = 0.014) and IL-18 (130.00 ± 28.58 pg/ml, F = 263.46, P = 0.002) release induced by LPS in combination with MPA [ Figure 4e ]. Therefore, caspase-1 was the key mediator in the synergy of MPA and LPS to stimulate IL-1β and IL-18 secretion.
dIscussIon
In the last few decades, extensive researches have demonstrated that immunosuppressants such as CYC, AZA, glucocorticoids, MMF, and cyclosporin A are capable of reducing lymphocyte proliferation as well as altering cytokine secretion such as IL-2, IL-6, IL-17, IL-5, and IL-13.
[ [23] [24] [25] [26] [27] However, immune suppression is commonly associated with opportunistic infections in clinical practice. Intravenous CYC plus steroid has been recognized as the standard protocol for severe lupus nephritis. [5] Unfortunately, this strategy has been usually correlated with severe opportunistic infections. [6, 7] Several studies have reported that in lupus nephritis induction therapy, MMF has been shown to be equivalent in effectiveness to intravenous CYC and superior to AZA with a more safety profile, [6] [7] [8] but the mechanism is still unclear. Previous results demonstrated that cytokine levels could be used to evaluate the immune status in patients with chronic heart failure or those exposed to immunosuppressants. [9] [10] [11] MPA is the active metabolite of MMF, which affects the de novo purine synthesis and consequently decreases lymphocyte proliferation. Surprisingly, although MPA decreased the secretion of IL-2 and IL-13 in PHA-treated whole blood, it dramatically promoted the secretion of IL-1β, [9] which contradicted the traditional conception that immunosuppressants inhibited the secretion of inflammatory factors. This study showed that whole blood cells, monocytes, and THP-1 cells treated with MPA in combination with LPS obviously augmented IL-1β [ Figures 1b, 2a, 2b, 3c and 4b] and IL-18 release [ Figure 4c ].
Therefore, we determined to investigate the mechanisms of MPA-mediated IL-1β release. We found that MPA had no effect on the expression of NF-κB p-p65 and intracellular pro-IL-1β protein [ Figure 3 ]. MPA treatment induced an increase in intracellular NLRP3 and activation of Figure 4d and 4e]. All these data indicated that the enhanced secretion of IL-1β by MPA in association with LPS was due to increased caspase-1 activity to accelerate the degradation of pro-IL-1β, rather than result from the increased generation of pro-IL-1β. Taken together, the data substantiated a "two-signal" model where LPS stimulation acted as the first signal for efficient production of intracellular pro-IL-1β and NLRP3 proteins. In addition, MPA or ATP activated the NLRP3 inflammasome as the second signal to induce proteolytic activity of caspase-1 that subsequently degraded the pro-IL-1β protein into mature IL-1β [ Figure 5 ]. This model could also account for increased IL-18 release after MPA treatment.
IL-1β could induce the synthesis of chemokines that can modulate macrophage, neutrophil, and T cell activity. [13, 28] IL-18 also potentially primed neutrophil and promotes early innate immune responses. [29] IL-1β and IL-18 indirectly participated in antiviral responses. [30] The survival of mice pretreated recombinant IL-1β was higher than control after LPS challenged.
[31] The mice deficient in IL-18 exhibited a higher mortality than wild-type mice while challenged with infection.
[32] IL-1 receptor-deficient mice (IL-1R-/-) showed fatal outcome during Staphylococcus aureus sepsis, and the number of Staphylococci was increased as compared with IL-1R+/+ mice. [33] Mice that were treated with IL-1R antagonist anakinra significantly increased the mortality induced by S. aureus. [34] All of these findings indicated that IL-1β as well as IL-18 played important roles in host defense. Therefore, we believed that the synergy of MPA with LPS to increase IL-1β and IL-18 release might contribute to a better infection defense in patients treated with MMF than those treated with CYC.
It was reported that prolonged production of IL-1β could lead to severe tissue and organ damage. [35] In this study, the finding that MPA induced IL-1β production was not contradictory to its immunosuppressive effect since the induction of IL-1β by MPA only happened in the presence of LPS, while MPA alone failed to do so [ Figures 1 and 2] . In other words, patients with autoimmune diseases treated with MMF could not produce IL-1β unless exposed to pathogens, for example, bacteria, indicating that the immune system of those patients receiving MMF might be properly suppressed while maintaining alert to bacterial infection.
In conclusion, this study has clarified that MPA synergized with LPS to enhance IL-1β release via the activation of caspase-1. These findings suggested that patients with autoimmune diseases who are treated with MMF might have highly activated caspase-1, which causes macrophages or monocytes to more readily release IL-1β in response to bacterial components, such as LPS. The data of this study provided experimental evidence as well as theoretical rationales for MMF to be included in immunosuppressive protocols that are not only more effective for transplant recipients or patients with autoimmune disorders but also enable the patients to be less liable to some bacterial infections. 
